advertisement
Abstract #8258 Published in IGR 4-3
A comparison of the fixed combination of latanoprost and timolol with its individual components
Pfeiffer NGraefe's Archive for Clinical and Experimental Ophthalmology 2002; 240: 893-899
PURPOSE: To evaluate the intraocular pressure (IOP)-reducing effect of the fixed combination of 0.005% latanoprost and 0.5% timolol compared with the individual monotherapies. METHODS: A six-month randomized, double-masked, controlled multicenter study followed by six months of open-label treatment was carried out in patients with glaucoma or ocular hypertension with pre-enrolment IOP ≥ 22 mmHg on glaucoma medication or ≥ 30 mmHg if untreated. Following a two- to four-week run-in period on timolol twice daily, 436 patients were randomized: 140 to fixed combination therapy once daily in the morning, 147 to latanoprost once daily in the morning, and 149 to timolol twice daily. During the open-label extension, patients received fixed combination drug once daily in the morning. RESULTS: The difference in mean change from baseline in diurnal IOP from week 2 to week 26 was -1.2 mmHg between fixed combination and latanoprost (95% confidence interval (CI): -1.8 to -0.5; p < 0.001); repeated-measures analysis of covariance). The corresponding difference between fixed combination and timolol was -1.9 mmHg (95% CI -2.5 to -1.2; p < 0.001). No long-term drift in IOP was detected in patients treated for 12 months with fixed combination. All treatments were well tolerated with no major differences among groups in the incidence of clinically relevant adverse events. CONCLUSIONS: The fixed combination of 0.005% latanoprost and 0.5% timolol administered once daily in the morning for six months was more effective in reducing IOP than the individual components alone, and was effective over 12 months.
N. Pfeiffer, MD, Department of Ophthalmology, Mainz University, 55101 Mainz, Germany. pfeiffer@augen.klinik.uni-mainz.de
Classification:
11.3.4 Betablocker (Part of: 11 Medical treatment > 11.3 Adrenergic drugs)
11.4 Prostaglandins (Part of: 11 Medical treatment)
